Healthcare
SELLAS Life Sciences Group, Inc.(SLS)
Live Price
Offline$8.05
+3.74% today
Window Change
-13.53%
Window
May 29, 2026 โ Jun 18, 2026
- Market Cap
- $700.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +50.0%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars ยท May 29, 2026 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SELLAS Life Sciences Group, Inc. (SLS) is a Healthcare stock with a market cap of $700.00M and listed on NASDAQ. The stock last traded around $8.05 and down 13.5% across the available one-year price window (May 29, 2026 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +50.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +50.0%, free cash flow +19.8% with operating margin 0.0% and ROIC -39.3%. Stock Foundry combines SLS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +50.0%, while operating margin sits near 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SLS
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SLS Max Drawdown
-23.20%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SLS and SPY.
Company Overview
SELLAS Life Sciences Group, Inc.
NASDAQ Capital Market
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
- Leadership
- Angelos Stergiou
- IPO Date
- Mar 12, 2008
- Employees
- 15
- Street Address
- Times Square Tower
- Mailing
- New York City, NY, 10036
- Region
- New York City, NY, US
- Reporting Currency
- USD
- Investor Line
- 646 200 5278
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 10.7
Growth
- Revenue
- 0.0%
- EPS
- +50.0%
- Free Cash Flow
- +19.8%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -63.1%
- ROIC
- -39.3%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 10.72
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.